Lallemand Health Solutions’ SciX Event Gathers Scientists from Around the World To Discuss Probiotic Innovation

Mirabel, Canada, April 10, 2024 – Renowned scientists from across the globe convened in Montreal last week for the 13th edition of Lallemand Health Solutions’ Scientific Exchange event. This gathering provided a dynamic platform for sharing innovative scientific discoveries.

The conference program featured poster presentations that unveiled recent findings from both published and unpublished preclinical and clinical research, all conducted in close collaboration with Lallemand Health Solutions and its proprietary probiotic strains. These insights sparked discussions and nurtured new partnerships.

Scientific Collaboration Spells Success

Jérôme Panes, President and General Manager at Lallemand Health Solutions summarizes the week’s proceedings: “As scientists shared their ongoing research, we once again witnessed the remarkable potential of probiotics in diverse areas such as fertility, pregnancy, cognition, sleep, and skin health, to name only a few. Following in the footsteps of our founders, Lallemand remains committed to investing in research and development. Our valued partnerships with top researchers find fruitful ground during this event, where we exchange ideas and led probiotics into the future.”

SciX: Fostering Innovation

“SciX is an internal conference that brings together international collaborators to discuss research, development, and results. This year, we extended our invitation to rising startups and contract research organizations (CROs), introducing fresh tools and artificial intelligence to the research community,” explains Sylvie Binda, Vice President of Research and Development at Lallemand Health Solutions. “We are fortunate to collaborate with passionate and curious individuals who continually push the boundaries of science in documenting the microbiome and its various health implications. Their work has the potential to enhance the quality of life for people of all ages, from infants to seniors, worldwide. We extend our heartfelt thanks to all our valued partners,” Dr. Binda expresses. She also emphasizes the power of collective intelligence, where public and private organizations join forces to address modern health concerns effectively.”

If you would like to collaborate and develop a project with probiotics, please contact our team.

About research and development at Lallemand Health Solutions

The major R&D challenges focus on the development and characterization of the effects of first and new generation probiotics on human health. Lallemand Health Solutions has integrated platforms for preclinical, clinical, galenic and bioprocess development, and a dedicated R&D team of 40+ people, notably managing over twenty clinical trials on five continents.

Watch a video of the day here

SciX Conference Program

Women’s Health Segment

Pr. Sarah Lebeer, University of Antwerpen presented: Advancing Women’s Health Via Citizen Science and Research on The Vaginal Microbiome

Belén Orgaz PhD, Complutense University of Madrid, presented: Estrogen Metabolism of Six Ligilactobacillus Salivarius Strains Isolated from Human Milk and Vaginal Microbiota

Sylvie Binda PhD, vice-president of research and development at Lallemand Health Solutions presented: The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants: A Randomized, Double-Blind, Placebo-Controlled Study (MOM Study)

Ola Kassem MBBS, M.Sc., Clinical research specialist at Lallemand Health Solutions, presented: The Effects of Cerebiome® On Stress and Skin Health in Younger Adult Females: A Holistic Approach to Skin Health, An Open-Label Proof-Of-Concept Study.

Gut Health Segment

Pr. Carole Creuzenet, University of Western Ontario presented: Secretions of Lactic Acid Bacteria as Novel Anti-Helicobacter Pylori Agents

Joseph Wang PhD, Nimble Science Ltd, presented: Targeted and Reproducible Sampling of The Small Intestinal Microbiome with The Small Intestine Microbiome Aspirate Capsule Technology (SIMBA): Clinical Validation Against Endoscopy Aspirates and Its Prospective Use in A Probiotic Intervention Study For SIBO

Gut-Brain Axis Segment

Cory Munroe, Dalhousie University presented: Impact of Probiotic Supplementation on Cognition and Related Health Outcomes Among Video Gamers: Protocol Overview

Pr. Alex Parker, Université de Montréal presented: Probiotics as Therapeutics for Neurodegeneration

Pr. Nafissa Ismail, University of Ottawa presented: The Gut Microbiome: A Mediator of Stress-Induced Depression- And Anxiety-Like Behaviors in Males and Females.

Pr. Charles Morin, Université Laval presented Sleep: An Essential Pillar of Health

Innovation and Regulatory Segment

Lise Sanchez, INRAE, presented: Isolation And In Vitro Characterization of Novel Gut Infant Commensal Bacteria

Marion Schiavone PhD, scientist at Lallemand Animal Nutrition presented: The zebrafish (Danio rerio) model: an accurate model to screen the effect of heat-inactivated Lactobacillus on immune responses and gut barrier function

Philippe Langella PhD, INRAE presented: Potential Novel Uses of Faecalibacterium prausnitzii in Human Health

Yohan Attal PhD, Cyrebro Neurosignals, presented: Integration of Connected Devices in Clinical Studies: Challenges and Perspectives

Michael Steller, Health Canada, presented: Probiotics as Natural Health Products: Authorizing Products and Clinical Trials

Benoît Fouchaq, Biofortis, presented: Innovation and New Challenges in Clinical Research

Milos Stojanov PhD, CHUV Lausanne, presented: Seminal Microbiota and Its Impact on Spermatozoa Physiology

Heidi Hau PhD, Clinical Microbiomics, presented: Mapping Microbiome Frontiers: Innovative Approaches to Probiotic Development and Analysis

Rémi Peyraud PhD, iMEAN, presented: Digital Twin for Optimization of Probiotics Design and Production


About Lallemand Health Solutions – Leading Probiotics Forward.

With company roots dating back to the end of the nineteenth century, Lallemand Health Solutions, one of Lallemand’s business units, specializes in the development, production and marketing of bacteria- and yeast-based probiotic supplements for human health, food applications, nutricosmetics and contract development and manufacturing (CDMO). With its production facilities adhering to the highest quality standards, including Good Manufacturing Practices, and its ambitious research program with the Rosell Institute for Microbiome and Probiotics, Lallemand Health Solutions provides its partners with probiotic strains that are documented for various health applications including gut health, natural defenses, mental health, women’s health, skin health, oral health, metabolic health, and sport and babies’ applications. More than 600 probiotic formulas are currently marketed in more than 60 countries on five continents.

Media Contact

Marilou Luneau, Communications Manager, Lallemand Health Solutions